Palisade Bio, Inc. (PALI) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Carlsbad, CA, 미국. 현재 CEO는 J. D. Finley.
PALI 을(를) 보유 IPO 날짜 2007-03-30, 8 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $341.72M.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
